• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ASTCT 和 USCLC 关于蕈样霉菌病和塞扎里综合征异基因干细胞移植的临床实践建议。

ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome.

机构信息

Department of Dermatology, University of Minnesota, Minneapolis, Minnesota.

Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota.

出版信息

Transplant Cell Ther. 2024 Nov;30(11):1047-1060. doi: 10.1016/j.jtct.2024.08.020. Epub 2024 Sep 1.

DOI:10.1016/j.jtct.2024.08.020
PMID:39222792
Abstract

Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma (CTCL). While MF generally follows an indolent course, a subset of patients will experience progressive and/or treatment-refractory disease; Sézary syndrome is an aggressive lymphoma associated with high morbidity and mortality. Although allogeneic hematopoietic cell transplant (allo-HCT) is the only currently available potentially curative treatment modality for MF/SS there is no published guidance on referral criteria, transplant timing orallo-HCT approach. To develop consensus clinical practice recommendations, we performed a Delphi survey of 32 specialists in dermatology (n = 9), transplant hematology/oncology (n = 10), non-transplant hematology/oncology (n = 8), and radiation oncology (n = 5) from across the United States. Consensus required agreement of ≥75% of participants. Sixteen consensus statements were generated on four topics: (1) criteria for referral for consideration for allo-HCT, (2) allo-HCT preparative regimens and procedures (3) disease status at the time of allo-HCT, and (4) multidisciplinary management in the pre- and post-transplant settings. These clinical practice guidelines provide a framework for decision-making regarding allo-HCT for MF/SS and highlight areas for future prospective investigation.

摘要

蕈样肉芽肿(MF)和塞扎里综合征(SS)是最常见的皮肤 T 细胞淋巴瘤(CTCL)亚型。虽然 MF 通常呈惰性病程,但一部分患者会出现进行性和/或治疗抵抗性疾病;SS 是一种侵袭性淋巴瘤,与高发病率和死亡率相关。虽然异基因造血细胞移植(allo-HCT)是目前唯一可潜在治愈 MF/SS 的治疗方法,但对于转诊标准、移植时机或 allo-HCT 方法尚未有发表的指导意见。为了制定共识临床实践建议,我们对来自美国各地的 32 名皮肤科(n=9)、移植血液/肿瘤学(n=10)、非移植血液/肿瘤学(n=8)和放射肿瘤学(n=5)专家进行了德尔菲调查。共识需要≥75%的参与者达成一致。就四个主题产生了 16 个共识声明:(1)考虑 allo-HCT 的转诊标准,(2)allo-HCT 预备方案和程序,(3)allo-HCT 时的疾病状态,(4)移植前和移植后的多学科管理。这些临床实践指南为 MF/SS 的 allo-HCT 决策提供了框架,并强调了未来前瞻性研究的领域。

相似文献

1
ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome.ASTCT 和 USCLC 关于蕈样霉菌病和塞扎里综合征异基因干细胞移植的临床实践建议。
Transplant Cell Ther. 2024 Nov;30(11):1047-1060. doi: 10.1016/j.jtct.2024.08.020. Epub 2024 Sep 1.
2
ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndrome.美国血液与骨髓移植学会(ASTCT)和美国临床肿瘤学会(USCLC)关于蕈样肉芽肿和塞扎里综合征异基因干细胞移植的临床实践建议。
J Am Acad Dermatol. 2025 Aug;93(2):387-397. doi: 10.1016/j.jaad.2025.04.005. Epub 2025 Apr 6.
3
ISCL/EORTC-CLTG/USCLC recommendations for the diagnosis, staging and treatment of early-stage paediatric mycosis fungoides: a modified Delphi consensus. Part one: diagnosis and staging.国际皮肤淋巴瘤学会/欧洲肿瘤内科学会儿童蕈样肉芽肿协作组/美国皮肤淋巴瘤协作组关于儿童早期蕈样肉芽肿诊断、分期及治疗的建议:改良德尔菲共识。第一部分:诊断与分期
Br J Dermatol. 2025 Aug 18;193(3):405-414. doi: 10.1093/bjd/ljaf199.
4
Therapeutic advances for cutaneous T-cell lymphoma.皮肤T细胞淋巴瘤的治疗进展
Br J Dermatol. 2025 Jun 20;193(1):11-15. doi: 10.1093/bjd/ljaf105.
5
Interventions for mycosis fungoides.蕈样肉芽肿的干预措施。
Cochrane Database Syst Rev. 2012 Sep 12(9):CD008946. doi: 10.1002/14651858.CD008946.pub2.
6
Evaluating mogamulizumab in the treatment of primary cutaneous T-cell lymphoma.评估莫加莫拉单抗治疗原发性皮肤T细胞淋巴瘤的疗效。
Immunotherapy. 2025 Jun;17(8):551-559. doi: 10.1080/1750743X.2025.2520153. Epub 2025 Jun 24.
7
Mycosis Fungoides, Sézary Syndrome, and Cutaneous B-Cell Lymphomas: 2025 Update on Diagnosis, Risk-Stratification, and Management.蕈样肉芽肿、塞扎里综合征和皮肤B细胞淋巴瘤:2025年诊断、风险分层及管理的最新进展
Am J Hematol. 2025 Sep;100(9):1603-1628. doi: 10.1002/ajh.27735. Epub 2025 Jun 10.
8
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
9
Long-Term Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: An Italian Multicenter Collaborative Study.复发/难治性B细胞非霍奇金淋巴瘤异基因造血干细胞移植后的长期结局:一项意大利多中心协作研究
Transplant Cell Ther. 2025 Jun 18. doi: 10.1016/j.jtct.2025.06.004.
10
Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.莫格利珠单抗治疗既往治疗的蕈样真菌病和塞扎里综合征:NICE 单一技术评估的证据审查小组观点。
Pharmacoeconomics. 2022 May;40(5):509-518. doi: 10.1007/s40273-021-01098-3. Epub 2021 Oct 19.

引用本文的文献

1
Mycosis Fungoides, Sézary Syndrome, and Cutaneous B-Cell Lymphomas: 2025 Update on Diagnosis, Risk-Stratification, and Management.蕈样肉芽肿、塞扎里综合征和皮肤B细胞淋巴瘤:2025年诊断、风险分层及管理的最新进展
Am J Hematol. 2025 Sep;100(9):1603-1628. doi: 10.1002/ajh.27735. Epub 2025 Jun 10.